NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002
Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3280-3280
DOI: 10.1200/jco-26-01043 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Qi Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Qi Cheng, MD and Yujin Xu, MD, Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy o…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Qi Cheng, MD and Yujin Xu, MD, Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
ORCID-Profile: Qi Cheng
Zitieren
APA
Cheng, Q., & Xu, Y. (2026). NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002. Journal of Clinical Oncology, 44(33), 3280-3280. https://doi.org/10.1200/jco-26-01043
Vancouver
Cheng Q, Xu Y. NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002. Journal of Clinical Oncology. 2026;44(33):3280-3280. doi:10.1200/jco-26-01043
BibTeX
@article{Cheng2026,
author = {Cheng, Qi and Xu, Yujin},
title = {NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {33},
pages = {3280--3280},
doi = {10.1200/jco-26-01043}
}
EUVIMED